Skip to content
Screener

Free cash flow at other companies

Stryker logo
StrykerSYK
$1.06B+14.1%
Vericel logo
VericelVCEL
$14.26M+17,504%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$393.6M+20.0%
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$22.96M-14.7%
Bioventus logo
BioventusBVS
$18.91M-25.1%
Xtant Medical Holdings logo
Xtant Medical HoldingsXTNT
-$7.56M-930%

Other financials

Income statement

See full
Revenue$32.6M+15.6%
Net income$3.3M+183%

Balance sheet

See full
Cash & equivalents$38.4M-27.8%
Total debt$25.3M+1.0%
Total equity$137.3M-7.0%
Total assets$183.5M-2.2%

Cash flow

See full
Operating cash flow-$684.0K-262%
CapEx$1.4M-1.2%

Valuation

See full
Market cap$278.9M+123%
Enterprise value$265.74M+175%
P/S2.3×+1.0×

Profitability

See full
Net margin-3.4%-1.6pp
FCF margin0.5%

Returns & leverage

See full
Return on equity-2.9%-1.4pp
Debt / equity0.2×0.0×
Current ratio4.5×-1.7×

Where this comes from

Calculated from Anika Therapeutics’s reported figures.

The source filing: Anika Therapeutics’s 10-Q, filed July 29, 2026. Open the filing →

Filed
Jul 29, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001171843-26-005012

FAQ

What is Anika Therapeutics's free cash flow?
Anika Therapeutics (ANIK) reported free cash flow of -$2.13M in Q2 2026.
How has Anika Therapeutics's free cash flow changed year-over-year?
Anika Therapeutics's free cash flow decreased by 28.8% year-over-year, from -$1.66M to -$2.13M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.

Ask your AI about Anika Therapeutics's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude